Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰ/Ⅱ, Open-Label Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

NCT07297875 is registered in ClinicalTrials.gov with Abbisko Therapeutics Co, Ltd as lead sponsor.

NCT NCT07297875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07297875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰ/Ⅱ, Open-Label Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
Lead sponsor
Abbisko Therapeutics Co, Ltd
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 10, 2025
Completion date
March 15, 2031
Enrollment
110 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

achondroplasia